



## EnteroMedics to Present at the 29th Annual Canaccord Adams Global Growth Conference

ST. PAUL, Minn., Aug 04, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM) announced today that Mark B. Knudson, Ph.D., Chief Executive Officer, is scheduled to present at the Canaccord Adams' 29th Annual Global Growth Conference in Boston, MA on Tuesday, August 11th at 9:00 am ET. Dr. Knudson will provide an overview of the Company and an update on its VBLOC™ vagal blocking therapy development program.

The presentation will be webcast live and may be accessed by visiting EnteroMedics' website at [www.enteromedics.com](http://www.enteromedics.com). A replay of the webcast will also be available immediately after the conclusion of the presentation. Investors can access the webcast under "Press Room" in the "Investors" section of EnteroMedics' website.

About EnteroMedics Inc.

EnteroMedics is a development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity and other gastrointestinal disorders. EnteroMedics' proprietary neuroblocking technology, VBLOC(R) vagal blocking therapy, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. EnteroMedics has met its enrollment goal under an FDA-approved Investigational Device Exemption (IDE) for the EMPOWER(TM) Study using the Maestro(R) System, its initial product for the treatment of obesity. EnteroMedics is currently recruiting patients outside of the United States for a feasibility study examining VBLOC Therapy's effects on blood glucose levels in diabetic patients. For more information, visit [www.enteromedics.com](http://www.enteromedics.com).

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations, our losses since inception and for the foreseeable future; our lack of regulatory approval for our Maestro(R) System for the treatment of obesity; our inability to complete our EMPOWER(TM) pivotal trial and other clinical trials, or significant delays in the completion of our clinical trials; our ability to timely commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and VBLOC(R) vagal blocking therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; potential healthcare legislative reform and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the Company's Form 10-K dated March 12, 2009. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Caution-Investigational device. Limited by U.S. Federal law to investigational use.

The implantation procedure and usage of the Maestro(R) System carry some risks, such as the risk generally associated with laparoscopic procedures and those related to treatment as described in the EMPOWER(TM) clinical trial informed consent.

SOURCE: EnteroMedics Inc.

EnteroMedics Inc.  
Greg S. Lea, 651-789-2860  
[ir@enteromedics.com](mailto:ir@enteromedics.com)

Copyright Business Wire 2009